Beacon Capital Management LLC raised its holdings in Medtronic plc (NYSE:MDT – Free Report) by 56.3% in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 702 shares of the medical technology company’s stock after buying an additional 253 shares during the period. Beacon Capital Management LLC’s holdings in Medtronic were worth $55,000 as of its most recent SEC filing.
Other institutional investors have also modified their holdings of the company. LifeSteps Financial Inc. acquired a new position in Medtronic in the first quarter valued at $27,000. MeadowBrook Investment Advisors LLC acquired a new stake in shares of Medtronic in the 4th quarter valued at about $27,000. Lynx Investment Advisory purchased a new position in Medtronic during the 2nd quarter worth approximately $28,000. Tributary Capital Management LLC acquired a new position in Medtronic during the first quarter worth approximately $33,000. Finally, Riverview Trust Co purchased a new stake in Medtronic in the first quarter valued at approximately $39,000. Institutional investors and hedge funds own 82.06% of the company’s stock.
Medtronic Price Performance
MDT stock opened at $88.35 on Friday. The stock has a 50-day moving average price of $80.48 and a two-hundred day moving average price of $82.31. The company has a market cap of $113.29 billion, a PE ratio of 32.13, a price-to-earnings-growth ratio of 2.35 and a beta of 0.82. The company has a current ratio of 2.03, a quick ratio of 1.55 and a debt-to-equity ratio of 0.47. Medtronic plc has a 12-month low of $68.84 and a 12-month high of $89.24.
Medtronic Announces Dividend
The firm also recently announced a quarterly dividend, which will be paid on Friday, October 11th. Investors of record on Friday, September 27th will be issued a dividend of $0.70 per share. The ex-dividend date is Friday, September 27th. This represents a $2.80 annualized dividend and a dividend yield of 3.17%. Medtronic’s payout ratio is 101.82%.
Insider Buying and Selling
In other Medtronic news, CEO Geoffrey Martha sold 19,113 shares of the firm’s stock in a transaction dated Friday, June 7th. The stock was sold at an average price of $83.77, for a total value of $1,601,096.01. Following the transaction, the chief executive officer now directly owns 143,348 shares of the company’s stock, valued at $12,008,261.96. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 0.30% of the stock is owned by corporate insiders.
Analyst Upgrades and Downgrades
Several analysts recently commented on the stock. Royal Bank of Canada reiterated a “sector perform” rating and set a $92.00 price target on shares of Medtronic in a research note on Wednesday. Piper Sandler increased their target price on shares of Medtronic from $85.00 to $90.00 and gave the stock a “neutral” rating in a research note on Wednesday. Needham & Company LLC restated a “hold” rating on shares of Medtronic in a research report on Tuesday, August 20th. Barclays upped their price objective on Medtronic from $104.00 to $105.00 and gave the company an “overweight” rating in a research note on Thursday. Finally, The Goldman Sachs Group began coverage on Medtronic in a research note on Thursday, May 30th. They issued a “sell” rating and a $83.00 target price on the stock. One research analyst has rated the stock with a sell rating, nine have assigned a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat, Medtronic has a consensus rating of “Hold” and an average price target of $92.92.
View Our Latest Stock Report on Medtronic
About Medtronic
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.
Recommended Stories
- Five stocks we like better than Medtronic
- 3 Ways To Invest In Coffee, Other Than Drinking It
- CAVA Stock Rallies as Earnings Confirm It’s a Top Growth Play
- How Investors Can Find the Best Cheap Dividend Stocks
- 3 High Short-Interest Stocks Poised for a Rate Cut Squeeze
- What is a Bond Market Holiday? How to Invest and Trade
- MarketBeat Week in Review – 8/19 – 8/23
Want to see what other hedge funds are holding MDT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medtronic plc (NYSE:MDT – Free Report).
Receive News & Ratings for Medtronic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medtronic and related companies with MarketBeat.com's FREE daily email newsletter.